Clinical Trials · NCT06390904
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients
- Phase
- Phase 2/Phase 3
- Recruitment status
- Active Not Recruiting
- Sponsor
- Xiaojun Chen
- Enrollment
- 29
- Start date
- Jul 2022
- Locations
- 2 sites, China
- Primary endpoint
- Complete response (CR) rate within 28 weeks of treatment